Document 6516097

Proceedings of the ISPD 2006 — The 11th Congress of the ISPD
August 25 – 29, 2006, Hong Kong
Peritoneal Dialysis International, Vol. 27 (2007), Supplement 2
0896-8608/07 $3.00 + .00
Copyright © 2007 International Society for Peritoneal Dialysis
Printed in Canada. All rights reserved.
WHAT IS THE OPTIMAL FAT MASS IN PERITONEAL
DIALYSIS PATIENTS?
David W. Johnson
Department of Renal Medicine, University of Queensland at Princess Alexandra
Hospital, Brisbane, Queensland, Australia
Perit Dial Int 2007; 27(S2):S250–S254
www.PDIConnect.com
KEY WORDS: Body mass index; chronic kidney failure
therapy; nutrition status; peritonitis; risk factors; survival rate.
Correspondence to: D.W. Johnson, Department of Renal
Medicine, Level 2, Ambulatory Renal and Transplant Services
Building, Princess Alexandra Hospital, Ipswich Road,
Woolloongabba, Brisbane Queensland 4102 Australia.
david_johnson@health.qld.gov.au
S250
T
he mean body mass index (BMI) of incident end-stage
renal failure (ESRF) patients has risen progressively
since the mid-1980s. In Australia and New Zealand, the
mean BMI of patients commencing renal replacement
therapy increased to 26 kg/m2 in 2004 from 22.1 kg/m2
in 1982 (1). A similar study in the U.S. ESRF population
reported an increase in mean BMI to 27.5 kg/m2 in 2002
from 25.7 kg/m2 in 1995 (2). During this 7-year period,
the prevalence of total obesity and stage 2 obesity increased by 33% and 63% respectively. Moreover, for all
age groups, the BMI slope was approximately twice as
high in the incident ESRF population as in the U.S. general population.
This alarming increase in the prevalence of obesity in
the dialysis population can likely be attributed to several reasons, including the increased prevalence of obesity in the general population (3,4), the accentuated risk
of progression of chronic kidney disease to ESRF in obese
subjects (4–9), the reduced probability of listing obese
dialysis patients for renal transplantation (10), and a
paradoxical enhancement of survival in at least some
obese populations on dialysis as compared with nonobese ESRF patients (10–17). Moreover, obesity has been
suggested to possibly be more prevalent in peritoneal
dialysis (PD) patients than in hemodialysis (HD) patients
because of excessive peritoneal glucose absorption (18),
although this suggestion has been refuted by other studies (19–21).
The purpose of the present paper is to review the
studies examining the relationship between obesity and
outcomes in PD patients and to determine whether interventions targeting obesity in PD patients are efficacious and justified.
THE IMPACT OF OBESITY ON PD OUTCOME
Although obesity is widely recognized to be a risk factor for morbidity and mortality in the general population, a higher BMI has consistently been shown to be
Downloaded from http://www.pdiconnect.com/ by guest on September 30, 2014
The prevalence of obesity in peritoneal dialysis (PD)
populations has risen dramatically since the mid-1980s.
This epidemic has been driven by the increased prevalence
of obesity in the general population, the increased risk of
progression of chronic kidney disease to end-stage renal
failure (ESRF) in obese subjects, the reduced probability of
listing obese dialysis patients for renal transplantation, a
paradoxical enhanced survival in at least some obese populations on dialysis as compared with non-obese ESRF patients, and a possible adipogenic effect of excessive
peritoneal glucose absorption in PD. Although obesity has
consistently been associated with improved outcomes in hemodialysis, conflicting results have been seen in PD. In general, an elevated body mass index (BMI) has been associated
with a neutral or deleterious impact on PD outcomes, and
the relationship appears to be explained predominantly by
fat mass. Risk is also elevated in patients with a low BMI,
such that the “optimal BMI” appears to lie between
20 kg/m2 and 25 kg/m2. The mechanisms underpinning the
harmful effect of obesity appear to include increased peritonitis rate, proinflammatory effects, and a more rapid decline of residual renal function in obese patients. No proof
exists that weight reduction engenders an improvement in
outcome in PD patients, but the available studies suggest
that cautious weight reduction is advisable. A few studies
have demonstrated that clinically important and sustained
weight reduction can be successfully achieved through a
combination of individual meal plans, regular exercise, and
substitution of icodextrin for dextrose in the once-daily
long dwell.
PDI
JUNE 2007 – VOL. 27, SUPPL 2
JOHNSON
als in a prevalent cohort of 208 PD patients. Similarly, in
a randomized controlled trial of two different PD doses
in 965 CAPD patients (ADEMEX study), Paniagua et al.
(29) stratified patient outcomes according to tertiles of
three different indices of body size (body surface area,
calculated total body water, and BMI). They found no significant differences in survival between these strata, but
subjects were followed for only just over 2 years. A retrospective cohort study of 1675 HD and 1662 PD patients
enrolled in the United States Renal Data System (USRDS)
Dialysis Morbidity and Mortality Wave II Study (30) observed that obesity (BMI > 30 kg/m2) was associated with
improved survival in HD patients (adjusted HR: 0.89; 95%
CI: 0.81 to 0.99; p = 0.04), but not in PD patients (adjusted HR: 0.99; 95% CI: 0.86 to 1.15; p = 0.89). Similar
results were reported by Stack et al. (32) in 134,728 new
ESRF patients recorded on the USRDS Registry.
Many of the above studies may potentially have suffered from informative censoring bias as a result of evaluating prevalent rather than incident patients (33).
Moreover, most of the investigations were based on U.S.
populations, where the uptake of PD is very low, raising
the possibility of selection bias. In an attempt to better
define the relationship between obesity and outcome in
a larger cohort of incident PD patients where the selection of PD versus HD is more equal, my group performed
a retrospective analysis of data from the Australia and
New Zealand Dialysis and Transplantation Association
(ANZDATA) registry on 19,635 patients who commenced
renal replacement therapy in Australia or New Zealand
between 1991 and 2002, and who received PD treatment
at some stage during their dialysis career (31). Obesity,
defined as a BMI greater than 30 kg/m2, was independently associated with death during PD treatment (HR:
1.36; 95% CI: 1.14 to 1.54; p < 0.05) and technique failure (HR: 1.17; 95% CI: 1.07 to 1.26; p < 0.01). When BMI
was analyzed as a continuous variable, a J-shaped curve
was observed, with the greatest survival occurring in
patients with a BMI of 20 kg/m2. Survival decreased progressively with BMI values above and below that level.
POTENTIAL MECHANISMS UNDERLYING THE IMPACT OF BODY
SIZE ON PD OUTCOME
The apparently conflicting results regarding the effect
of body size on PD outcome may relate in part to the inability of BMI to differentiate between muscle mass and
fat tissue. Using 24-hour urinary creatinine excretion as a
measure of muscle mass, Ramkumar et al. (34) examined
the influence of body composition on survival in 10,140
incident PD patients. Patients with a high BMI and normal
or high muscle mass had lower risks of all-cause mortality
S251
Downloaded from http://www.pdiconnect.com/ by guest on September 30, 2014
associated with reduced mortality risk in patients undergoing HD (13,15,16,22–24). The role of body size in
PD has been less well investigated than it has in HD, and
studies have variously reported a propitious (10,17,
25,26), neutral (27–30), or deleterious effect of BMI on
PD outcome (31,32).
The first investigation of the impact of BMI on PD patient outcome was a 3-year observational cohort study
of 43 prevalent PD patients at my center (17). Using multivariate Cox proportional hazards model analysis, a BMI
greater than 27.5 kg/m2 was found to be a positive predictor of patient survival [adjusted hazard ratio (HR):
0.09; 95% confidence interval (CI): 0.01 to 0.85; p <
0.05], independent of other clinical, biochemical, nutritional, and echocardiographic parameters. Overweight patients also tended to experience fewer fatal
myocardial infarctions (adjusted HR: 0.33; 95% CI: 0.07
to 1.48; p = 0.15), although this difference was not statistically significant.
In contrast, Fried et al. (27) showed that survival in
patients whose body weights were more than 1 standard
deviation above the mean (82.7 kg) was not significantly
different from that seen in the rest of the adult PD population. However, when the data were reanalyzed using
body surface area, a significant positive correlation was
found between that parameter and survival.
A retrospective study of 242 incident CAPD patients
(25) reported that individuals with a body weight greater
than 80 kg spent significantly fewer days in hospital and
had rates of peritonitis, technique survival, and death
that were similar to those of patients weighing between
60 kg and 80 kg. Another retrospective study of 41,197
Medicare PD patients in the United States (10) similarly
demonstrated that the overall survival rate was slightly
higher in obese patients (BMI > 30 kg/m2) after 1 year
(HR: 0.89), but was similar at 2 and 3 years (HR: 0.99
and 1.00 respectively).
Johansen et al. (26) analyzed 418,055 patients starting dialysis in the United States between April 1995 and
November 2000 (including 44,869 patients on PD) and
observed increased survival and reduced hospitalization
risk in the overall cohort, even at extremely high BMI. This
positive association remained when alternative estimates
of adiposity, including Benn index and estimated fat mass,
were substituted for BMI. However, the beneficial effect
was blunted in PD patients as compared with HD patients,
such that enhanced survival could be demonstrated only
in the BMI range between 25 kg/m2 and 31 kg/m2.
Other published studies have generally found that
obesity has a neutral effect on outcome in PD patients.
For example, Aslam et al. (28) reported comparable
2-year survival rates in obese and non-obese individu-
PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD
OBESITY IN PD
PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD
JOHNSON
S252
individuals is the observed proinflammatory effect of
adipose tissue (41).
IS THERE ANY EVIDENCE THAT WEIGHT REDUCTION IS
ASSOCIATED WITH IMPROVED PD PATIENT OUTCOMES?
The short answer to the question of whether weight reduction is associated with improved patient outcomes in
PD is no. Nevertheless, based on the hypothesis-generating observations of a generally neutral or deleterious effect of obesity on PD outcomes, primarily associated with
inferred high fat mass, it would appear reasonable to cautiously advise weight reduction in obese individuals receiving PD. To date, only one study has been published of a
multidisciplinary (dietitian, nurse, physiotherapist)
weight reduction program in PD patients. This program
comprised a 12-month intervention with individual meal
plans, a regular exercise program, augmentation of peritoneal small-solute clearance, and optimization of the PD
prescription to reduce caloric load in 11 PD patients, each
having a BMI exceeding 25 kg/m2 (42). Only 8 patients
completed the study, of whom 7 experienced a sustained,
significant weight loss (median weight change to 89.5 kg
from 94.6 kg; p = 0.017). This weight loss was associated
with a fall in resting and post-exercise heart rates, but no
other changes in indices of cardiovascular fitness or quality-of-life scores were discernible.
Substituting icodextrin for dextrose in PD solution may
also reduce caloric load, particularly in high transporters.
A recent double-blind randomized controlled trial of icodextrin versus 2.5% dextrose solution for the once-daily
long dwell in 175 PD patients reported weight stabilization in the icodextrin group (–0.3 kg) as compared with a
significant increase in body weight in the control group
(+2.33 kg) over a period of 1 year. However, a significant
component of this difference in weight gain may have been
attributable to differences in body fluid status, because
significantly fewer patients reported edema in the icodextrin group (6.3% vs. 17.9%, p < 0.01).
Pharmacotherapy has also been advocated for weight
reduction, but most of the available agents (benzphetamine, phendimetrazine, diethylpropion, phentermine,
sibutramine, orlistat, rimonabant) are considered contraindicated in the presence of severe chronic kidney disease. Laparoscopic banding may need to be considered for
extreme obesity.
CONCLUSIONS
Obesity is an increasingly common problem in PD
populations, with a rate of increase that is more than
double that seen in the general population. This alarm-
Downloaded from http://www.pdiconnect.com/ by guest on September 30, 2014
(HR: 0.90; 95% CI: 0.83 to 0.97) and cardiovascular mortality (HR: 0.88; 95% CI: 0.79 to 0.97) than did those with
a normal BMI and normal or high muscle mass. Moreover,
high-BMI patients with low muscle mass (and therefore
an inferred high fat mass) had higher observed risks of
all-cause mortality (HR: 1.29; 95% CI: 1.17 to 1.42) and
cardiovascular mortality (HR: 1.21; 95% CI: 1.06 to 1.39).
Thus, the harmful effects of high BMI in PD patients were
limited to individuals with (inferred) high body fat; normal or high muscle mass conferred a protective effect.
Part of the mechanism underlying a deleterious effect of obesity on PD outcome may be an increased risk
of PD-related infection. Piraino et al. (35) observed a
trend toward higher peritonitis rates in 228 incident PD
patients as the ratio of actual to ideal body weight increased from less than 0.9 (underweight: 0.8 episodes
per year) to between 0.9 and 1.1 (normal weight:
0.9 episodes per year) to greater than 1.1 (overweight:
1.0 episode per year). Moreover, these investigators observed that catheter losses from infection were significantly higher in overweight PD patients.
A subsequent analysis of incident Australia and New
Zealand PD patients demonstrated that obese individuals had a poorer peritonitis-free survival than did patients of lesser body weight (36). Every 5 kg/m2 increase
in BMI was associated with a 7% increase in the risk of a
first peritonitis episode. Similarly, the overall rate of
peritonitis, when expressed as episodes per year of PD
treatment, was higher in obese individuals. Every
5 kg/m2 increase in BMI was associated with a 14% increase in the risk of a first peritonitis episode. Thus,
obese PD patients were more likely to experience infection, which in turn contributed to their poorer outcomes.
An alternative possibility is that the more frequent occurrence of peritonitis and poorer overall outcomes in
obese patients reflect a greater tendency for this group
to be underdialyzed. Small-solute clearance in PD is less
efficient than in HD, which may be particularly limiting
in large patients (37). In the Australia and New Zealand
study, technique failure in obese (as compared with
other) patients was more likely to result from inadequate
small-solute clearance (underweight 13%, normal
weight 18%, overweight 20%, obese 23%; p < 0.01).
Moreover, RRF, loss of which is strongly correlated with
PD peritonitis (38), has recently been found to decline
at a more rapid rate in obese patients than in normal or
underweight PD patients (39).
Interestingly, in a subsequent analysis of the Australia and New Zealand study, my group demonstrated that,
after adjustment for RRF, obesity no longer predicted
mortality in PD patients (40). A plausible, though unproven, hypothesis for the more rapid loss of RRF in obese
JUNE 2007 – VOL. 27, SUPPL 2
PDI
OBESITY IN PD
PDI
JUNE 2007 – VOL. 27, SUPPL 2
JOHNSON
REFERENCES
1. Johnson DW, McDonald SP, Excell L, Livingston B,
Shtangey V. Peritoneal dialysis. In: McDonald SP, Excell
L, eds. ANZDATARegistry Report 2005. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant
Registry; 2006: 84–100.
2. Kramer HJ, Saranathan A, Luke A, Durazo–Arvizu RA,
Guichan C, Hou S, et al. Increasing body mass index and
obesity in the incident ESRD population. J Am Soc Nephrol
2006; 17:1453–9.
3. Dunstan D, Zimmet P, Welborn T, Sicree R, Armstrong T,
Atkins R, et al. Diabesity and associated disorders in Australia 2000. Melbourne: International Diabetes Institute;
2001.
4. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V,
Fonseca V, et al. The metabolic syndrome and CKD in U.S.
adults. Ann Intern Med 2004; 140:167–74.
5. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ,
Merrill D, et al. Relationship between nutritional status
and the glomerular filtration rate: results from the MDRD
study. Kidney Int 2000; 57:1688–703.
6. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D.
Predictors of new-onset kidney disease in a communitybased population. JAMA 2004; 291:844–50.
7. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S.
Influence of smoking and obesity on the development of
proteinuria. Kidney Int 2002; 62:956–62.
8. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK,
Nyren O. Obesity and risk for chronic renal failure. J Am
Soc Nephrol 2006; 17:1695–702.
9. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body
mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21–8.
10. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ.
Body size and outcomes on peritoneal dialysis in the
United States. Kidney Int 2003; 64:1838–44.
11. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK,
Young EW. Body mass index and mortality in “healthier”
as compared with “sicker” haemodialysis patients: results
from the Dialysis Outcomes and Practice Patterns Study
(DOPPS). Nephrol Dial Transplant 2001; 16:2386–94.
12. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ.
Simple nutritional indicators as independent predictors
of mortality in hemodialysis patients. Am J Kidney Dis
1998; 31:997–1006.
13. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P,
et al. Mortality risk factors in patients treated by chronic
hemodialysis. Report of the Diaphane collaborative study.
Nephron 1982; 31:103–10.
14. Fleischmann E, Teal N, Dudley J, May W, Bower JD,
Salahudeen AK. Influence of excess weight on mortality
and hospital stay in 1346 hemodialysis patients. Kidney
Int 1999; 55:1560–7.
15. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-forheight relationships predict mortality in maintenance
hemodialysis patients. Kidney Int 1999; 56:1136–48.
16. Wiesholzer M, Harm F, Schuster K, Putz D, Neuhauser C,
Fiedler F, et al. Initial body mass indexes have contrary
effects on change in body weight and mortality of patients
on maintenance hemodialysis treatment. J Ren Nutr 2003;
13:174–85.
17. Johnson DW, Herzig KA, Purdie DM, Chang W, Brown AM,
Rigby RJ, et al. Is obesity a favorable prognostic factor in
peritoneal dialysis patients? Perit Dial Int 2000; 20:
715–21.
18. Heimbürger O. Obesity on PD patients: causes and management. Contrib Nephrol 2003; (140):91–7.
19. Jager KJ, Merkus MP, Huisman RM, Boeschoten EW, Dekker
FW, Korevaar JC, et al. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001;
12:1272–9.
20. Nordfors L, Heimbürger O, Lonnqvist F, Lindholm B,
Helmrich J, Schalling M, et al. Fat tissue accumulation
during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. Kidney Int 2000; 57:
1713–19.
21. Davies SJ, Russell L, Bryan J, Phillips L, Russell GI. Impact of peritoneal absorption of glucose on appetite, protein catabolism and survival in CAPD patients. Clin Nephrol
1996; 45:194–8.
22. Fleischmann E, Teal N, Dudley J, May W, Bower JD,
Salahudeen AK. Influence of excess weight on mortality
and hospital stay in 1346 hemodialysis patients. Kidney
S253
Downloaded from http://www.pdiconnect.com/ by guest on September 30, 2014
ing increase in the prevalence of obesity in PD patients
is being driven by an increased risk of progression of
chronic kidney disease to ESRF in obese subjects, a reduced probability of listing obese dialysis patients for
renal transplantation, paradoxically enhanced survival
of at least some obese populations on dialysis as compared with non-obese ESRF patients, and a possible
adipogenic effect of excessive peritoneal glucose absorption in PD.
Although obesity has consistently been associated
with improved outcomes in HD, the results in PD are conflicting, generally showing a neutral or deleterious effect of elevated BMI. The harmful effect appears to be
attributable to fat mass rather than to lean body mass,
and it may be mediated by an increased peritonitis rate,
proinflammatory effects, and more rapid decline of RRF
in obese patients. There is no proof that weight reduction engenders an improvement in patient outcome on
PD, but the available studies suggest that promoting
weight reduction to achieve a BMI between 20 kg/m2 and
25 kg/m2 is reasonable. Some limited evidence demonstrates that weight reduction can be successfully
achieved through a combination of individual meal plans,
regular exercise, and substitution of icodextrin for dextrose in the once-daily long dwell.
PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD
OBESITY IN PD
PROCEEDINGS OF THE 11TH CONGRESS OF THE ISPD
JOHNSON
S254
33. Vonesh EF, Moran J. Mortality in end-stage renal disease:
a reassessment of differences between patients treated
with hemodialysis and peritoneal dialysis. J Am Soc
Nephrol 1999; 10:354–65.
34. Ramkumar N, Pappas LM, Beddhu S. Effect of body size
and body composition on survival in peritoneal dialysis
patients. Perit Dial Int 2005; 25:461–9.
35. Piraino B, Bernardini J, Centa PK, Johnston JR, Sorkin MI.
The effect of body weight on CAPD related infections and
catheter loss. Perit Dial Int 1991; 11:64–8.
36. McDonald SP, Collins J, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and
New Zealand peritoneal dialysis patient populations. Perit
Dial Int 2004; 24:340–6.
37. Tzamaloukas AH, Murata GH. Peritoneal dialysis in patients with large body size: can it deliver adequate clearances? Perit Dial Int 1999; 19:409–14.
38. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI,
Oreopoulos DG. Rate of decline of residual renal function
in patients on continuous peritoneal dialysis and factors
affecting it. Perit Dial Int 2000; 20:429–38.
39. Johnson DW, Mudge DW, Sturtevant JM, Hawley CM,
Campbell SB, Isbel NM, et al. Predictors of residual renal
function decline in new peritoneal dialysis patients. Perit
Dial Int 2003; 23:276–83.
40. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality
and technique failure in the Australian and New Zealand
peritoneal dialysis patient populations. J Am Soc Nephrol
2006; 17:271–8.
41. Stompor T, Sulowicz W, Dembinska–Kiec A, Janda K, Wojcik
K, Zdzienicka A. An association between body mass index
and markers of inflammation: is obesity the proinflammatory state in patients on peritoneal dialysis? Perit Dial
Int 2003; 23:79–83.
42. Hollis J, Corden E, Williams PF. Longitudinal evaluation
of a weight reduction program for patients on peritoneal
dialysis. Perit Dial Int 2005; 25(Suppl 3):S152–4.
Downloaded from http://www.pdiconnect.com/ by guest on September 30, 2014
Int 1999; 55:1560–7.
23. Wiggins K, Johnson DW. The influence of obesity on the
development and survival outcomes of CKD. Adv Chronic
Kidney Dis 2005; 12:49–55.
24. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ.
Simple nutritional indicators as independent predictors
of mortality in hemodialysis patients. Am J Kidney Dis
1998; 31:997–1006.
25. Afthentopoulos IE, Oreopoulos DG. Is CAPD an effective
treatment for ESRD patients with a weight over 80 kg? Clin
Nephrol 1997; 47:389–93.
26. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324–32.
27. Fried L, Bernardini J, Piraino B. Neither size nor weight
predicts survival in peritoneal dialysis patients. Perit Dial
Int 1996; 16:357–61.
28. Aslam N, Bernardini J, Fried L, Piraino B. Large body mass
index does not predict short-term survival in peritoneal
dialysis patients. Perit Dial Int 2002; 22:191–6.
29. Paniagua R, Amato D, Vonesh E, Correa–Rotter R, Ramos
A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX,
a prospective, randomized, controlled trial. J Am Soc
Nephrol 2002; 13:1307–20.
30. Abbott KC, Glanton CW, Trespalacios FC, Oliver DK, Ortiz
MI, Agodoa LY, et al. Body mass index, dialysis modality,
and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65:597–605.
31. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc
Nephrol 2003; 14:2894–901.
32. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among “large”
ESRD patients in the United States. Kidney Int 2004; 65:
2398–408.
JUNE 2007 – VOL. 27, SUPPL 2
PDI
OBESITY IN PD